Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 9.6a

Immunosuppression Use for Induction, 1999 to 2008

Recipients with Liver Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 4,751 4,997 5,196 5,332 5,673 6,171 6,444 6,651 6,494 6,318
With Immunosuppression Info 4,442 4,846 5,034 5,198 5,520 5,974 6,164 6,407 6,276 6,125
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 0.7% 0.7% 0.4% 0.5% 0.5% 0.4% 0.2% 0.3% 1.2% 1.1%
OKT3 1.4% 0.8% 0.7% 0.3% 0.3% 0.2% 0.8% 2.7% 2.9% 2.5%
Thymoglobulin 0.5% 1.2% 2.4% 4.2% 6.5% 7.4% 7.3% 8.9% 9.5% 10.3%
Zenapax 6.6% 6.6% 5.8% 4.6% 5.6% 4.7% 4.0% 5.8% 8.1% 7.9%
Simulect 4.4% 6.6% 6.2% 7.8% 7.2% 6.4% 7.1% 6.5% 5.6% 6.7%
Campath 0.0% 0.0% 0.0% 0.0% 0.7% 1.6% 1.6% 1.4% 1.4% 1.0%
No Induction Drugs Recorded 86.7% 84.5% 84.6% 82.7% 79.5% 79.5% 79.9% 77.2% 74.4% 73.4%


Source: OPTN/SRTR Data as of May 4, 2009.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader